Recent Updates
Recently added Catalysts

Burch Modified Tanagho, Autologous Fascia Sling

Phase 2

Urinary Incontinence | Unknown | Nephrology |Elevance Health, Inc.|Last Updated: May 10, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment655

FDA Designations

No designations recorded

Clinical trial landscape

Burch Modified Tanagho, Autologous Fascia Sling · 1 trial · 1 indication

Phase 2 1
NCT00064662Comparison of Surgical Procedures to Reduce Urinary Stress IncontinenceUrinary Incontinence
COMPLETED655 Analytics
PHASE2COMPLETED
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
Urinary IncontinenceUnlock trial analytics

Study Endpoints

Primary Endpoints

24 Month Cumulative Success Rate Computed From Kaplan Meier Time-to-event Analysis (Reported as Percent Success).
Two years

Success defined as composite measure including: no self-reported incontinence symptoms reported on the Medical, Epidemiologic, and Social Aspects of Aging Project (MESA) questionnaire, \<15g in pad weight during 24 hr pad test, no incontinence episodes on 3-day voiding diary, negative results (no leakage) on provocative stress test at standardized bladder volume, no retreatment for urinary incontinence. Additional treatment for stress urinary incontinence (SUI) includes anti-incontinence surgery, tightening of sling, collagen injections, medication, behavioral treatment, or devices specifically for the treatment of SUI.

24 Month Cumulative Stress Specific Success Rates Computed From Kaplan Meier Time-to-event Analysis (Reported as % Success)
Two years

Stress-specific success defined by composite measure including: no self-reported symptoms of stress incontinence reported on the Medical, Epidemiologic, and Social Aspects of Aging Project (MESA) questionnaire , negative results (no leakage) on a provocative stress test at standardized bladder volume and no retreatment for stress incontinence Additional treatment for SUI includes anti-incontinence surgery, tightening of sling, collagen injections, medication, behavioral treatment, or devices specifically for the treatment of SUI.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
BurchOTHERThe Burch colposuspension
SlingOTHERPubovaginal sling, using autologous rectus fascia

Interventions

NameTypeDescription
Burch Modified TanaghoPROCEDUREThe Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
Autologous Fascia SlingPROCEDUREThe fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to N/A
SexFEMALE
Healthy VolunteersYes
Study Sites9

* Predominant stress urinary incontinence by self-report,examination and test; * Urethral hypermobility; * Eligible for both surgical procedures; * Ambulatory; * Not pregnant; * \>12 months post-partum; * No systemic disease known to affect bladder function; * No current chemotherapy or radiation th...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Burch Modified Tanagho, Autologous Fascia Sling

What is Burch Modified Tanagho, Autologous Fascia Sling used for?

Burch Modified Tanagho, Autologous Fascia Sling is used for urinary incontinence. It is an investigational surgical procedure being studied in a Phase 2 clinical trial that compares surgical approaches to reduce stress urinary incontinence in women.

Who is developing Burch Modified Tanagho, Autologous Fascia Sling?

Burch Modified Tanagho, Autologous Fascia Sling is being developed by Elevance Health, Inc., which trades under the ticker ELV. The company is conducting clinical research on this surgical procedure for urinary incontinence.

What phase is Burch Modified Tanagho, Autologous Fascia Sling in?

Burch Modified Tanagho, Autologous Fascia Sling is in Phase 2 clinical development. It is an investigational procedure, not yet approved, and is being evaluated in a completed Phase 2 trial for urinary incontinence.

What clinical trials is Burch Modified Tanagho, Autologous Fascia Sling in?

Burch Modified Tanagho, Autologous Fascia Sling is studied in clinical trial NCT00064662, titled "Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence." This Phase 2 trial enrolled 655 female participants aged 21 years and older in the United States.

Is Burch Modified Tanagho, Autologous Fascia Sling the same as a sling procedure?

Burch Modified Tanagho, Autologous Fascia Sling is a surgical procedure that uses autologous fascia, meaning tissue taken from the patient's own body, to create a sling. It is being compared with other surgical procedures in a clinical trial for stress urinary incontinence.